Silicon Laboratories reported a return to profitability in the third quarter of 2026 with net income of $8.9 million, compared to a net loss of $9.9 million in the prior year period. However, for the nine months ended October 3, 2026, the company remains in a net loss position of $17.6 million as revenues grew to $692.6 million from $576.6 million year-over-year.
Silicon Laboratories reported Q3 2026 revenue of $251 million, a 22% year-over-year increase driven by record medical revenue and broad-based growth in Industrial & Commercial and Home & Life segments. GAAP diluted EPS improved to $0.26 from a loss in the prior year, while non-GAAP EPS rose 228% to $1.05. The company suspended forward-looking guidance due to its pending acquisition by Texas Instruments.
Term
Q3 2026
“We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued. Earnings significantly outpaced revenue growth, a result of strong operational execution by the team. Looking ahead, our current backlog and design-win ramps position us for continued revenue growth and meaningful earnings expansion.”
Matt Johnson, President and Chief Executive Officer